ClinicalTrials.gg
CompletedNCT06939504Updated Jul 8, 2025

A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects

A Phase 1 interventional study of HRS-9813 Capsule and HRS-9813 Tablet in Pulmonary Fibrosis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.

Enrollment
28th of 30
12 · median 146
Started
2025
with 4 others
Phase 1
9 of 40
1 open now
Registered
33rd of 40
by date
Lead sponsor
2 of 40
Guangdong Hengrui Pharmaceutical Co., Ltd

Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 28th largest by enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 1, and was the 33rd registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.

03

Conditions studied

  • Pulmonary Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 18-45 years.
  2. Male weight ≥ 50 kg, female weight ≥ 45 kg, and (BMI): 19-26 kg/m2.
  3. Subjects not with vital signs and laboratory tests.
  4. Take measures.

Exclusion criteria

Exclusion Criteria:

  1. Any serious clinical diseases that affect the absorption, metabolism and/or excretion of the study drug.
  2. Severe infection, severe trauma or major surgery.
  3. Any medications in the two weeks before screening or baseline period.
  4. History of blood donation or severe blood loss.
  5. Have been vaccinated within 2 weeks before the screening or baseline period.
  6. History of smoking or excessive alcohol or drug abuse.
  7. Other situations that the researcher judges to be unsuitable.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    HRS-9813 Capsule Group

    Drug: HRS-9813 Capsule

  • Experimental
    HRS-9813 Tablet Group

    Drug: HRS-9813 Tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed concentration of HRS-9813 capsule (Cmax)

    Time frame: Day 1-Day 23.

  2. Maximum observed concentration of HRS-9813 tablet (Cmax)

    Time frame: Day 1-Day 23.

  3. Area under the concentration-time curve from time 0 to infinity of HRS-9813 tablet (AUC0-inf)

    Time frame: Day 1-Day 23.

  4. Area under the concentration-time curve from time 0 to infinity of HRS-9813 capsule (AUC0-inf)

    Time frame: Day 1-Day 23.

Secondary outcomes

  1. Adverse events (AEs)

    Time frame: Day 1-Day 23.

  2. Time to Cmax of HRS-9813 capsule (Tmax).

    Time frame: Day 1-Day 23.

  3. Time to Cmax of HRS-9813 tablet (Tmax).

    Time frame: Day 1-Day 23.

07

Study locations

1 site
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200120, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Jun 2025, 0 months.

Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2025
First posted
Apr 22, 2025
StartActual
May 4, 2025
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 23, 2025
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06939504
Responsible party
Sponsor
First posted
Apr 22, 2025
Start date
May 4, 2025
Primary completion
Jun 3, 2025
Completion
Jun 23, 2025
Last update
Jul 8, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9813

Start the discussion